News

The worst might be in the rearview mirror.

Novo Nordisk A/S (NYSE:NVO) presented new analyses from its phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 in Istanbul, highlighting the long-term weight loss potential and functional benefits of its oral obesity treatment, Wegovy pill. The company said adults treated with oral semaglutide 25 mg achieved clinically meaningful weight loss regardless of whether they experienced rapid early reductions in body weight. Early Responders Saw Greater Long-Term Weight Loss Accord

The European stock markets were trending higher in Wednesday trading as investors monitor President

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr

This data could help support Novo in its bid to claw back market share taken by Eli Lilly in the obesity space.

Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez have been highlighted in this Investment Ideas article.

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Novo Nordisk presented new data at the European Congress on Obesity on high dose Wegovy (semaglutide 7.2 mg) from the STEP UP and SELECT trials and a large real world study. The results show substantial and consistent weight loss for women across life stages, including menopause, alongside reductions in body fat. The data highlight additional benefits tied to cardiovascular and mental health, including reduced risks of heart attack, stroke, migraine, and depression in menopausal...

Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Stre

Hims & Hers drops after posting unexpected quarterly loss

Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.

European stock markets fell in late Tuesday trading as oil prices rose after negotiations between th

With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.

Hims & Hers slashed its profitability outlook for 2026. The news sent Hims stock into free fall Tuesday morning.

US equity futures were lower pre-bell Tuesday as the standoff continued in the Middle East, with the

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

↗️ Venture Global (VG): The liquefied-natural-gas exporter, which stands to benefit from the closure of the Strait of Hormuz, is due to report results this morning, potentially shedding light on the strength of demand.

By Amina Niasse and Siddhi Mahatole May 11 (Reuters) - Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company's shift

Cellular Intelligence gains rights to Novo's early-stage Parkinson's program and plans a mid-stage study early next year.

The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.

Investing.com -- Hims & Hers missed first-quarter earnings estimates, posting a loss as weakness in its American operations offset gains overseas.

Novo Nordisk (CPSE:NOVO B) has licensed its clinical-stage allogeneic cell therapy program for Parkinson's disease to Cellular Intelligence. The program includes an ongoing Phase 1/2 trial and holds FDA Fast Track status. Novo Nordisk is exiting direct cell therapy operations while taking an equity stake in Cellular Intelligence. Cellular Intelligence plans to use its AI platform to support development of the Parkinson's therapy. Novo Nordisk, trading at DKK300.6, is best known for its GLP...

Eli Lilly faces challenges in the GLP-1 market, with Novo Nordisk gaining a timing advantage in both injectable and oral drug approvals.

Cellular Intelligence is acquiring STEM-PD, a Phase 2-ready cell therapy, and plans to use AI to accelerate development and manufacturing

Novo Nordisk shuttered its cell therapy unit in October 2025, with assets now moving to new hands.

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.